| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |